Fennec Pharmaceuticals Inc.
FRX.TOTSXHealthcare● Active
$12.44
$-0.28(-2.20%)
Market Cap$355535511
P/E Ratio—
52W High$14.24
52W Low$7.59
Fennec Pharmaceuticals Inc. (FRX.TO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · FRX.TO · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $45.42M | $47.54M | $21.25M | $1.53M | $0.00M |
| Cost of Revenue | $3.83M | $3.18M | $1.26M | $0.09M | $0.00M |
| Gross Profit | $41.59M | $44.35M | $19.99M | $1.45M | $0.00M |
| Gross Margin %(computed) | 91.57% | 93.30% | 94.08% | 94.40% | — |
| Operating Expenses | |||||
| R&D Expenses | $0.25M | $0.31M | $0.06M | $3.53M | $4.98M |
| G&A Expenses | $0.00M | $23.05M | $20.59M | $17.72M | $12.24M |
| Total Operating Expenses | $48.46M | $41.79M | $32.76M | $24.04M | $17.22M |
| Operating Income | ($6.86M) | $2.57M | ($12.77M) | ($22.59M) | ($17.22M) |
| Operating Margin %(computed) | -15.11% | 5.40% | -60.09% | — | — |
| Interest Income | $0.80M | $1.68M | $0.44M | $0.20M | $0.05M |
| Interest Expense | $2.18M | $4.07M | $3.39M | $0.98M | $0.13M |
| Income Before Tax | ($10.27M) | ($0.07M) | ($16.05M) | ($23.71M) | ($17.35M) |
| Income Tax Expense | $0.00M | $0.36M | $0.00M | $0.15M | $0.11M |
| Net Income | ($10.27M) | ($0.44M) | ($16.05M) | ($23.86M) | ($17.46M) |
| Net Margin %(computed) | -22.62% | -0.92% | -75.50% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.36 | $-0.02 | $-0.60 | $-0.91 | $-0.67 |
| Wtd Avg Shares | 28.58M | 21.80M | 26.57M | 26.27M | 25.89M |
| EBITDA | ($6.86M) | $4.80M | ($12.65M) | ($22.74M) | ($17.18M) |
| EBITDA Margin %(computed) | -15.11% | 10.09% | -59.53% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Fennec Pharmaceuticals Inc. data
About Fennec Pharmaceuticals Inc. (FRX.TO) Income Statement
Fennec Pharmaceuticals Inc. (FRX.TO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, FRX.TO reported revenue of $0.05B, gross profit of $0.04B (gross margin 91.57%), and net income of ($0.01B) — a net profit margin of -22.62%.
Frequently asked questions
FRX.TO · 4 questionsFennec Pharmaceuticals Inc. (FRX.TO) reported revenue of $0.05B for 2025, down 4.4% year-over-year.
FRX.TO revenueFRX.TO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08